#54 - Dalibor Sames: When the Researcher Finally Takes the Medicine

What happens when a world class chemist studies a molecule for twenty years and then finally takes it himself? In this episode of Ibogaine Uncovered, host Talia Eisenberg speaks with Dr. Dalibor Sames about the science of ibogaine, its unique pharmacology, and what it reveals about the future of mental health treatment.

Dr. Sames explains why ibogaine does not fit into traditional pharmacology models and introduces his matrix pharmacology theory, describing how the molecule interacts with many systems at once rather than a single receptor. The conversation covers synaptic repair, neurotrophic factors like GDNF, antidepressant effects, and why ibogaine shows efficacy across addiction, depression, PTSD, and TBI. In the second half, Dr. Sames describes his time at Beond as both participant and observer, including vivid visual phenomena, an unexpected moment where he felt he could “see” molecular structures, and the takeaway he emphasizes after watching clients transform in real time: this is powerful technology and scaling it demands responsibility.

Dr. Dalibor Sames is Professor of Chemistry at Columbia University, where his group combines molecular design, organic synthesis, and pharmacology to develop CNS therapeutics that induce restorative neuroplasticity, as well as tools for imaging synaptic function. He is also a cofounder of Gilgamesh Pharmaceuticals and Kures, Inc., translating discoveries from his lab into clinical development.

Timestamps

• (00:05:00) GDNF and neurorestoration: why synapses became the entry point

• (00:08:00) Skepticism vs the clinical reports: breakthrough medicine or snake oil

• (00:10:00) The “empty screen” problem: why standard receptor panels did not explain it

• (00:12:00) Matrix pharmacology: the Manhattan traffic grid analogy for how it works

• (00:15:00) Why analogs: cardiac risk, access, and the ethics of redesigning nature

• (00:20:00) Serotonin transporter and pharmaco chaperoning: unusual protein folding effects

• (00:22:00) “Meets you where you are”: individuality of experience and doing science on subjectivity

• (00:25:00) Why take it now: what changes when the scientist becomes the participant

• (00:33:00) Pre Beond phenomena: the African face vision and possible explanations

• (00:40:00) The Beond journey: projections, maintaining baseline awareness, and asking for molecules

• (00:47:00) Beond as living lab: observing client transformations and the responsibility to scale safely

• (00:54:00) Closing thesis: duty, antibiotics analogy, and what comes next